04/06/2019
Minoryx Therapeutics announces first patient dosed in the FRAMES phase 2 trial in Friedreich’s Ataxia
Minoryx Therapeutics, a company specializing in the development of new drugs for orphan diseases, today announces that the first patient has been dosed with its lead candidate, leriglitazone (MIN- 102), in the phase 2 FRAMES clinical trial in Friedreich’s Ataxia. [...]
